STAT

DECEMBER 4, 2023

The Senate health care committee will consider a sweeping bill next week meant to combat the opioid epidemic, according to four lobbyists and a congressional aide familiar with the legislation.  The proposal would reauthorize a number of programs first created by the SUPPORT Act, an addiction-focused bill that Congress first passed in 2018. Many of those programs’ authorizations expired earlier this year, however, leading addiction treatment advocates to fret that lawmakers —

359

359

PharmaVoice

DECEMBER 4, 2023

Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

246

246

STAT

DECEMBER 4, 2023

OK, marijuana is now legal. So where’s the public health approach? Strictly speaking, marijuana use isn’t fully legal across the U.S. yet. But when Montana and Missouri have legalized recreational use and the Senate is debating legal banking for cannabis companies, you know it’s all over but the shouting.

358

358

PharmaVoice

DECEMBER 4, 2023

AstraZeneca’s Gemma Satterthwaite talks to the company’s ambition to transform the entire care experience for patients with blood cancers.

246

246

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

DECEMBER 4, 2023

Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes.  The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary.

Documentation 342

Documentation 342

ALiEM - Pharm Pearls

DECEMBER 4, 2023

A 49-year-old male presented to the emergency department of an academic hospital with the chief concern of penile pain. Prior medical history is notable for end-stage renal disease on hemodialysis three times per week, but the patient has not been dialyzed in the past four days, hypertension, insulin-dependent diabetes mellitus, heart failure with reduced ejection fraction (59% two months prior), seizure disorder, prior pulmonary embolism (eight months prior), a left nephrectomy seven months ago

Hospitals 150

Hospitals Medical Schools Diabetes 150

PharmaVoice

DECEMBER 4, 2023

Hindsight offers a better perspective on why some deals are fruitful and others fail.

163

163

STAT

DECEMBER 4, 2023

The medical community today faces a deceptively simple question: How quickly should we act when a child’s life is on the line? I’m a pediatric oncologist, so my answer won’t surprise you — I think we should act immediately. But a new Food and Drug Administration policy could delay things for children who need treatment now.

Chemotherapy 318

Chemotherapy 318

The Pharmacist

DECEMBER 4, 2023

NHS England (NHSE) has released optional guidance on shared workforce models for pharmacists, although the Company Chemists’ Association (CCA) has warned that complexity could hinder their uptake. The guidance, published last week, sets out optional workforce models that community pharmacies and hospital pharmacy departments may wish to consider in collaboration with primary care networks (PCNs). […] The post Doubts raised over NHSE shared workforce guidance for pharmacists appeared first

Community Pharmacies 119

Community Pharmacies Hospitals 119

STAT

DECEMBER 4, 2023

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. How sickle cell became the first CRISPR’d disease Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes.

Hospitals 239

Hospitals 239

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

The Pharmacist

DECEMBER 4, 2023

Nearly three-quarters of respondents to a survey by the Association of Independent Multiple Pharmacies (AIMp) expressed the view that Community Pharmacy England (CPE) is not currently representative of community pharmacies in England. Among almost 380 responses, 73.8% opted for ‘no’ in answer to the question of, ‘Do you think CPE is currently representative of community […] The post AIMp survey suggests dissatisfaction with CPE representation appeared first on The Pharmacist.

Community Pharmacies 115

Community Pharmacies 115

STAT

DECEMBER 4, 2023

In the wake of the Covid-19 pandemic, the Food and Drug Administration inspected far fewer domestic and foreign pharmaceutical facilities, even though manufacturing activity did not decline, according to a new analysis. Meanwhile, FDA budgeting and staffing held steady, although resources allocated for each inspection surged and more plants were cited for serious violations.

Pharmaceutical Manufacturing 225

Pharmaceutical Manufacturing 225

pharmaphorum

DECEMBER 4, 2023

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that if consummated will thrust it into the increasingly competitive market for incretin-based therapies for diabetes and obesity. The Swiss pharma group has agreed to pay $2.7 billion upfront in cash when the deal closes, with shareholders in the US company also in line for up to $400 million if the drug programmes covered by the agreement meet various milestones.

Diabetes 110

Diabetes 110

STAT

DECEMBER 4, 2023

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so familiar routine of online meetings, phone calls, and deadlines has predictably returned. But you knew this would happen, yes? After all, the world, such as it is, somehow keeps spinning. So time to nudge it in a better direction with a fresh cup of stimulation.

Drug Development 219

Drug Development 219

Pharma Times

DECEMBER 4, 2023

In England, an estimated 4,500 people are living with undiagnosed HIV - News - PharmaTimes

142

142

STAT

DECEMBER 4, 2023

WASHINGTON — The Supreme Court on Monday wrestled with a nationwide settlement with OxyContin maker Purdue Pharma that would shield members of the Sackler family who own the company from civil lawsuits over the toll of opioids. The justices seemed by turns relucant to break up an exhaustively negotiated agreement, but also leery of somehow rewarding the Sacklers.

218

218

Express Pharma

DECEMBER 4, 2023

How has your work on the biology of G-protein coupled receptors (GPCRs) helped pharma companies increase the efficacy of medicines for common diseases like diabetes, hypertension etc.? About half of the currently prescribed medicines work through GPCRs by turning them on or off. However, the signaling mechanism downstream of GPCRs is very complexes and involves multiple pathways operating in parallel.

Diabetes 108

Diabetes 108

STAT

DECEMBER 4, 2023

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hiya. Today, we explore how traditionally underserved sickle cell patients became early recipients of a futuristic gene-editing therapy, see another generative AI drug discovery deal forged, and more.

Drug Pricing 191

Drug Pricing Drug Development 191

The Guardian - Pharmaceutical Industry

DECEMBER 4, 2023

Modern medicine makes it seem as if drugs are the only way to deal with diabetes. But what if diet can be a solution? One gray Sunday in the middle of the Covid lockdown, I received an unwelcome call from my family doctor. Until then, for virtually my entire life, I had managed to stay out of a doctor’s office, except for routine checkups. My luck had run out.

Diabetes 111

Diabetes 111

Express Pharma

DECEMBER 4, 2023

Vibcare Healthcare has inaugurated a manufacturing facility in Panchkula, Haryana, built with an investment of Rs 40 crores. The company informed, spanning over five acres, the facility adheres to international standards, including EU GMP, PIC/S and UKMHRA GMP. Siddharth Singhal, CEO of Vibcare Healthcare said, “This groundbreaking facility affirms our dedication to excellence in pharma.

103

103

World Pharma News

DECEMBER 4, 2023

Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.

Diabetes 101

Diabetes 101

Express Pharma

DECEMBER 4, 2023

Takeda announced the signing of a three-year MoU with the Biotechnology Industry Research Assistance Council (BIRAC), a public sector enterprise set up by the Department of Biotechnology, Government of India. The MoU was announced in the presence of Dr Jitendra Singh, Union Minister of State for Science & Technology, Minister of State for the Prime Minister Office, Government of India, and senior government and industry leaders.

103

103

BioPharma Dive

DECEMBER 4, 2023

The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was "non-inferior" to Regeneron's Eylea.

103

103

European Pharmaceutical Review

DECEMBER 4, 2023

The European Commission (EC ) has authorised ZILBRYSQ ® (zilucoplan)▼ as the first once-daily subcutaneous (SC), targeted peptide inhibitor of complement component 5 (C5) inhibitor for generalised myasthenia gravis ( gMG ). It is also the only C5 inhibitor approved for self-administration by adult patients who are AChR antibody-positive with this disease.

Labelling 98

Labelling 98

Express Pharma

DECEMBER 4, 2023

Akums Drugs and Pharmaceuticals announced the acquisition of a new formulation facility located in Baddi, Himachal Pradesh. This marks the twelfth formulation facility under Akums, and the second in Baddi. The newly acquired facility, sprawling across approximately six acres, is currently undergoing upgrades and is slated to become operational in the year 2024.

99

99

BioPharma Dive

DECEMBER 4, 2023

The acquisition of Carmot, which had been planning an IPO, will hand Roche three weight loss medicines in early clinical testing.

115

115

European Pharmaceutical Review

DECEMBER 4, 2023

The (bio)pharmaceutical industry is currently facing numerous hurdles in its path to high-efficiency production that are more complex and pressing than ever before. One of the most significant perceived challenges is the ability to implement new innovations and increase productivity while adhering to stringent regulatory demands. The race to develop new drugs and therapies demands rapid drug discovery, testing and time-to-market.

Pharmaceutical Manufacturing 92

Pharmaceutical Manufacturing 92

BioPharma Dive

DECEMBER 4, 2023

Accurate and timely processing of data is imperative to create robust analytical datasets that can be used in the RWE setting.

115

115

European Pharmaceutical Review

DECEMBER 4, 2023

A report published by MarketsandMarkets has estimated that the pharmaceutical excipients market will value $14.9 billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. This is compared to the expected revenue for the market in 2023 reaching $10.7 billion. Excipients market opportunities and limitations Major contributing factors regarding growth of the pharmaceutical excipients market are: increasing demand for generic drugs and drug products, increased investment in R&D for

Pharmaceutical Companies 92

Pharmaceutical Companies Pharmaceutical Companies 92

BioPharma Dive

DECEMBER 4, 2023

With clinical trials becoming more complex, finding ways to streamline and automate laboratory processes is vital when analyzing bioanalytical samples.

102

102

Pharma Times

DECEMBER 4, 2023

The neurological condition affects around 50 million people worldwide - News - PharmaTimes

121

121

Pharmaceutical Commerce

DECEMBER 4, 2023

Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.

102

102

Pharmaceutical Technology

DECEMBER 4, 2023

Eli Lilly has received approval from the US FDA for Jaypirca to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL)

96

96

The Pharmacist

DECEMBER 4, 2023

Community Pharmacy England (CPE) has written to chancellor Jeremy Hunt to express concern over the potential financial impact of the upcoming rise in the National Living Wage (NLW). Signed by Janet Morrison, CPE chief executive, the letter also called for a ‘targeted funding uplift’ to the core contract. The government’s recently announced minimum wage hike […] The post Minimum wage hike ‘unsustainable’ with low funding, CPE warns Hunt appeared first on The Pharmacist.

Community Pharmacies 75

Community Pharmacies 75

Pharmaceutical Technology

DECEMBER 4, 2023

Roche has signed an agreement for the acquisition of US-based company Carmot Therapeutics in a deal valued at $2.7bn, to be paid in cash.

98

98